BG-60366 / BeOne Medicines - LARVOL DELTA

BG-60366-101: A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=33 | Terminated | Sponsor: BeOne Medicines | Recruiting ➔ Terminated; Evaluation on business strategy, not involving safety issue.

Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BG-60366-101: A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=33 | Terminated | Sponsor: BeOne Medicines | Active, not recruiting ➔ Terminated; Evaluation on business strategy, not involving safety issue.

Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BeOne shelves 5 cancer programs… (FierceBiotech) - "Four of the five cancer assets have been discontinued entirely, BeOne announced in its May 6 earnings presentation (PDF). These are the EGFR-targeting BG-60366, which was in development for lung cancer; a pan-KRAS inhibitor called BGB-53038 for lung and gastrointestinal tumors; MAT2A inhibitor BG-89894 for lung and solid tumors; and CDK2 inhibitor BG-68501, for breast and solid tumors....A study of the CCR8 antibody BGB-A3055 in solid tumors has also been terminated, but this asset has not been fully discontinued, a BeOne spokesperson confirmed to Fierce Biotech."

Discontinued • Trial termination • Esophageal Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer

BG-60366-101: A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=33 | Active, not recruiting | Sponsor: BeOne Medicines | N=93 ➔ 33 | Trial completion date: Apr 2028 ➔ May 2026 | Trial primary completion date: Apr 2028 ➔ May 2026 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (ChiCTR) - P1 | N=258 | Not yet recruiting | Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Update (Businesswire) - "Anticipate...internal proof-of-concept data for BG-60366 (EGFR CDAC), BGB-53038 (panKRAS inhibitor), BG-C137 (FGFR2b ADC), BGB-C354 (B7H3 ADC), and BG-C477 (CEA ADC) in the second half of 2025."

P1 data • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BG-60366-101: A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=93 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=93 | Not yet recruiting | Sponsor: BeiGene

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor